leucovorin or levoleucovorin

Phase 3Small molecule

leucovorin or levoleucovorin is one of 42 small molecule programs targeting Malignant Neoplam. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant NeoplamNot yet recruiting

Esophageal AdenocarcinomaActive, not recruiting

Malignant NeoplamPhase 2

Not yet recruiting

Esophageal AdenocarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Esophageal Adenocarcinoma

#DrugCompanyPhaseTrials

Ellence

Eloxatin

10 3

Taxol

Teva

Phase 3

9 4

Keytruda

Merck & Co.

Phase 3

6 5

Lenvima

Eisai

Phase 3

1 6

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

7 7

Paraplatin

AAvyxa

Phase 3

6 8

Taxotere

AAvyxa

Phase 3

4 9

Adrucil

EElorac, Inc.

Phase 3

3 10

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

PreclinicalRecruiting

Colorectal Cancer

NCT06428409

Q3 2030

Phase 2Not yet recruiting

Malignant Neoplam

NCT07793942

Clinical

Trials by Indication[1]

Colorectal Cancer2 trials

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT05839470·20 enrolled

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06428409·220 enrolled

Esophageal Adenocarcinoma1 trial

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04662710·895 enrolled

Malignant Neoplam1 trial

A Phase 2, Open-label Clinical Study to Evaluate the Safety and Efficacy of MK-2010 as Monotherapy and in Combination

Not yet recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07793942·480 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for leucovorin or levoleucovorin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — leucovorin or levoleucovorin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for leucovorin or levoleucovorin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

leucovorin or levoleucovorin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Q3 2030

Trials by Indication[1]

Colorectal Cancer2 trials

Esophageal Adenocarcinoma1 trial

Malignant Neoplam1 trial

References

Drug Info

Quick Facts

Related News